With just a painless, one-time-only, five-minute topical treatment, patients can better protect their smile as Florida biopharmaceutical company Oragenics Inc. revealed its brand-new patented process recently in Tampa to reduce the incidence of dental caries.
Oragenics’ SMaRT Replacement Therapy received a 17-year-long patent protecting not only its pharmaceutical compositions but also other delivery forms such as mouthwash, toothpaste, chewing gum, floss, chewable tablet, and food and beverage products.
"I am thrilled that the improvements that we engineered in the SMaRT Therapy will afford Oragenics additional intellectual property which could enable us to attempt to demonstrate the safety and efficacy of this novel therapy in the clinic," Dr. Jeffrey Hillman, co-inventor of SMaRT technology and Oragenics Inc.’s co-founder and retired Chief Science Officer, said.
The United States Patent and Trademark Office issued U.S. Patent No. 9,260,488 titled “Replacement Therapy for Dental Caries,” assuring the firm of exclusive product rights for the near future.
“Dr. Hillman’s pioneering work continues to provide potentially new opportunities for improved health care and significant patient benefits,” said Oragenics’ Chairman Dr. Frederick Telling.
Oragenics develops novel antibiotics to fight the world’s most prevalent infectious diseases. Additionally, the company creates and markets proprietary OTC probiotics specifically designed to enhance oral health for humans and pets.